Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RLYB
HoldHot AirRallybio Corporation · Healthcare · United States · $89M · Avg Vol: $271K/d
54
StockRankGet insider-trade alerts
Q
36
V
47
M
65
P/E (TTM)
2.1x
ROE
64.9%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0.6M | 0.9M | 34.9% | 0.6M |
| EPS | -16.72 | -14.72 | -10.64 | -1.59 | — | 7.99 |
| Shares | 4.7M | 4.7M | 5.2M | 5.3M | +11.7% | 5.3M |
| Debt | 0.6M | 0.4M | 0.2M | 0.2M | -31.8% | — |
| Equity | 169.3M | 106.2M | 61.7M | 58.0M | -30.0% | — |
| Op CF | -57.3M | -60.3M | -49.3M | -29.8M | — | 26.7M |
| Inv CF | -112.2M | 27.7M | 33.5M | 47.3M | — | — |
| Fin CF | 51.1M | 0.1M | 5.2M | 16.0K | — | — |
Loading 1Y...
PRICE (1Y)+4.2%
SMA 50SMA 200
Close
$16.75
RSI (14)
53.9
52W High
$17.57
From 52W High
1.0%
SCORE BREAKDOWN
Quality
36
ROIC
-55.4%14.2
ROE
64.9%98.4
GP/Assets
-26.6%3.5
Op. Margin
-3935.4%3.9
FCF/Assets
-28.9%14.6
Piotroski
321.8
Int. Cover
—N/A
D/E Ratio
0.00x90.9
Current Ratio
27.27x97.7
Value
47
P/E (TTM)
2.1x99.8
EV/EBITDA
0.1x25.0
P/FCF
—N/A
P/B
1.0x86.9
P/S
139.1x5.9
Div Yield
—N/A
Momentum
65
52W High %
95%95.3
RS 6M
55%92.6
SMA 50/200
1.50x97.7
EPS Rev 4W
0.0%34.4
EPS Rev 12W
—N/A
EPS Improve
-168%3.1
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$89M
P/E (Forward)
-3.1x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RLYB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RLYB | Rallybio Corporation(you) | $89M | 54 | Hold |
| FBIO | Fortress Biotech, Inc. | $92M | 45 | Hold |
| SPRO | Spero Therapeutics, Inc. | $70M | 67 | Buy |
| ICCC | ImmuCell Corporation | $90M | 74 | Buy |
| BSEM | BioStem Technologies, Inc. | $63M | 39 | Hold |
| XLO | Xilio Therapeutics, Inc. | $59M | 38 | Hold |
| BOLD | Boundless Bio, Inc. | $64M | 36 | Hold |
| ACRV | Acrivon Therapeutics, Inc. | $88M | 29 | Sell |
| APLM | Apollomics, Inc. | $77M | 28 | Sell |
| CSBR | Champions Oncology, Inc. | $68M | 30 | Sell |
Peer medians: ROE -30.7% · P/E 27.1x · Gross margin 58.3%